An interventional study of Pelvic Floor Muscle Therapy Website in Pelvic Floor Disorder and Pelvic Floor Muscle Exercise, sponsored by Yale University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Yale University · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Pelvic Floor Disorders with a site in United States — 12 open to participants now, 16 under way, none of them phase 3. Pelvic Floor Disorders · United States.
Among the 61 studies in Pelvic Floor Disorders with a site in United States, this one is the 36th largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2025, is one of 38 with no phase, reaches primary completion later than 5 of the 15 other live ones, and was the 52nd registered.
212 studies on the registry are indexed under Pelvic Floor Disorders; 46 are open to participants now.
Browse Pelvic Floor Disorders studies →12 of the 61 studies in Pelvic Floor Disorders with a site in United States are open now. Recruiting first, the newest first:
Cassandra Kisby · Sites in United States
Ages 21+ · Women only
University of Cincinnati · Sites in United States
Ages 18+ · Women only
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+ · Women only
University of Miami · Sites in United States
Ages 18–75 · Women only
NICHD Pelvic Floor Disorders Network · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Pelvic Floor Disorders studies recruiting now, 17 (63%) set no upper age limit and 10 (37%) stop at 75 or younger; none take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 64 across 148 interventional studies indexed under Pelvic Floor Disorders.
Median enrollment 57 across the 50 interventional studies, 133 across the 11 observational. Of the 38 that completed or were terminated, 15 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 61 have an industry lead sponsor. The 10 most frequent:
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
Yale University has 1 study filed under Pelvic Floor Disorders — fewer than ten, so there is no comparison to draw.
8 of the studies in Pelvic Floor Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT06689891Yale UniversityVideo-Based Pelvic Floor Muscle Therapy | 2026-12 |
| NCT06111209Brigham and Women's HospitalThe Anabolic Effect of Testosterone on Pelvic Floor Muscles | 2026-12-31 |
| NCT06796985University of MiamiBotox for Chronic Pelvic Pain | 2027-03-22 |
| NCT06798311University of ChicagoReducing Disparities in Urinary Control Symptoms for Minority Women | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 61 studies in Pelvic Floor Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a feasibility, pilot trial of remote, video-based pelvic floor muscle therapy (PFMT) for patients with pelvic floor disorders, including pelvic organ prolapse, urinary incontinence and anorectal dysfunction. PFMT has been shown to improve these symptoms in multiple studies.
This will be a feasibility and acceptability trial of a novel remote, web-accessible PFMT curriculum, designed by pelvic floor physical therapists.
Patients will be expected to complete a 5-10-minute survey at initial enrollment. They will have one in-person session with a pelvic floor therapist prior to starting the 8-week video-based PFMT course. Afterwards, they will have a final in person session with a pelvic floor therapist along with a final set of surveys that should take an estimated 10-15 minutes.
The primary objective is to the determine the feasibility and accessibility of using a video-based PFMT for patients with pelvic floor dysfunction.
The secondary objective is to determine whether video-based PFMT can improve symptomatology and quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will complete a series of surveys before and after the intervention. They will complete 8 weeks of video-based PFMT with an initial and final in-person session with a pelvic floor therapist.
Device: Pelvic Floor Muscle Therapy Website
8-week video-based, self-directed PFMT course
System Usability Scale (SUS) Score
The SUS is a 10-question survey that measures how easy a product or system is to use. Total score range from 0-100 with higher scores indicating better usability.
Time frame: 8 weeks
Percentage of participants video completion
Percentage of participants that complete at least 80% of the videos
Time frame: 8 weeks
Change in graded evaluation of exercises by pelvic floor therapist
Participants will be assessed and graded and by the pelvic floor physical therapist as below: 1 - cannot perform exercise, 2 - can partially perform exercise (needs some cueing and assistance), 3 - can independently perform exercise
Time frame: baseline and 8 weeks
Adverse Events
Number of participants that experience at least one adverse event.
Time frame: up to 8 weeks
Short Form-12 (SF-12)
The SF-12 is an abbreviated version of the SF-36. The SF-12 is a validated survey that assesses a patient's health related quality of life across eight domains. The total score range is 0-100 with a physical component summary and a mental component summary. A higher score indicates better health for each of those components.
Time frame: baseline and week 9
Cleveland Clinic Incontinence Score (CCIS)
The CCIS is a health-related quality of life measure that assesses how often and to what degree incontinence affects a person's life. The total score ranges from 0 to 20, with higher scores indicating higher levels of incontinence.
Time frame: baseline and week 9
Patient Assessment of Constipation Symptoms (PAC-SYM)
The PAC-SYM is a questionnaire used to assess the severity of constipation symptoms in adults. Total score range 0-4 with higher scores indicating more severe constipation.
Time frame: baseline and week 9
International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF)
The ICIQ-SF is a brief patient-completed questionnaire that measures the impact of urinary incontinence (UI) on quality of life (QoL). The ICIQ-UI SF is scored on a scale of 0-21. A score of zero means no urine leakage and no impact on QoL.
Time frame: baseline and week 9
Pelvic Organ Prolapse Symptom Score (POP-SS)
The POP-SS is a questionnaire that measures the severity of pelvic organ prolapse symptoms. The total score ranges from 0-28, with higher scores indicating more severe symptoms.
Time frame: baseline and week 9
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.
Of 100 non-industry interventional studies with no phase under Pelvic Floor Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's planned 18 months is close to that.
Counting every sponsor, half of 106 studies reached it within 17 months; a quarter within 7 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.